查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1474866

小分子创新者 API CDMO 市场规模、份额、趋势分析报告：按阶段类型、客户类型、治疗领域、地区、细分市场预测，2024-2030 年

Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Customer Type, By Therapeutic Area, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 241 Pages | 商品交期: 2-10个工作天内

价格

小分子创新者 API CDMO 市场成长与趋势：

根据 Grand View Research, Inc. 的最新报告，预计到 2030 年，全球小分子创新药 API CDMO 市场规模将达到 471.4 亿美元，2024 年至 2030 年复合年增长率为 6.53%。

製药公司外包趋势的上升、小分子药物需求的增加以及临床试验数量的快速增加预计将对市场产生积极影响。製药业越来越多使用 CDMO 的原因有很多，其中成本效益是一个突出因素。外包已成为製药公司透过避免昂贵的基础设施和资本投资来减少开支的有效策略。 CDMO 提供必要的专业知识和基础设施，以在财务上审慎的方式提供药物开发和製造服务。

此外，提高效率也是製药外包的关键驱动力。随着製药公司面临更快将新药推向市场的压力，外包已成为加速药物开发过程的解决方案。 CDMO 利用其专业知识、经验和最先进的设备来促进高品质药品的快速高效生产，并使製药公司能够满足开发进度。此外，随着新疗法和孤儿药的不断涌入，以及已通过核准产品收益的增加，一些製药公司正在选择 CDMO 来利用先进的基础设施和专业知识。此外，CDMO 持续的技术进步提供了创新的小分子原料药，可以满足医疗产业对创新、效率和监管合规性日益增长的需求。

当公司采用先进技术时，他们可以改善药物开发、製造流程和生产力。製药业对新型小分子创新 API 的需求不断增长，正在推动商业 CDMO 产能扩张，预计将推动市场成长。例如，2023年8月，Astex宣布与默沙东达成合作研究和授权合约，将小分子候选物与肿瘤抑制蛋白一起分类，用于癌症治疗。根据协议，该公司将利用其基于片段的药物发现平台开发化合物，并向默沙东提供先导化合物以进行临床前开发和优化。

小分子创新者 API CDMO 市场报告亮点

  • 2023年，临床阶段细分市场占据市场主导地位，份额为54.68%。该领域的成长是由于各种製剂的临床试验（I-III 期）活动的增加、小分子开发平臺的扩大、专业知识的可用性的增加以及创新带来的缩短时间且更具成本效益的临床实验药物开发所活性化的。此外，资金筹措也支持该产业的成长。
  • 按客户类型划分，由于先进药物开发的药物研发快速进步，製药领域在 2023 年占据最大份额。此外，各种治疗方法的进步已将製药公司的 CDMO 重点转向开发新型小分子创新 API 药物来治疗多种疾病。
  • 癌症治疗领域占据市场主导地位，2023年占42.25%的份额。全球癌症发生率的上升推动了这一领域的发展。此外，对创新小分子创新原料药的需求不断增加、标靶治疗的进步以及对癌症药物创新的需求是推动癌症治疗领域的因素。
  • 由于慢性病盛行率不断上升、对小分子原料药和 CDMO 服务的需求以及医疗基础设施的改善，亚太地区在 2023 年将占据市场份额 41.53%。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章 小分子创新者 API CDMO 市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
  • 技术景观
  • 按阶段和地区分類的临床试验总数（2021-2023）
  • 小分子创新者 API CDMO 市场：分析工具
  • COVID-19 对小分子创新者 API CDMO 市场的影响
  • COVID-19 影响分析

第四章小分子创新者 API CDMO 市场：阶段类型估计与趋势分析

  • 细分仪表板
  • 全球小分子创新药API CDMO市场波动分析
  • 2018-2030 年全球小分子创新 API CDMO 市场规模及趋势分析（依阶段类型）

第五章小分子创新者 API CDMO 市场：客户类型估计与趋势分析

  • 细分仪表板
  • 全球小分子创新药API CDMO市场波动分析
  • 2018-2030年全球小分子创新药物API CDMO市场规模与趋势分析（依顾客类型）

第六章小分子创新者API CDMO市场：治疗领域的估计与趋势分析

  • 定义和范围
  • 2023 年和 2030 年治疗领域市场占有率
  • 细分仪表板
  • 全球小分子创新药API CDMO市场波动分析
  • 2018-2030 年全球小分子创新药物 API CDMO 市场规模与趋势分析（依治疗领域）

第 7 章 小分子创新者 API CDMO 市场：区域估计与趋势分析

  • 区域市场仪表板
  • 全球区域市场概述
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第八章 竞争格局

  • 市场参与企业分类
  • 服务热力图分析（玩家间比较分析）
  • 公司简介
  • 供应商情况
    • Key company market share analysis, 2023
    • Lonza Group Ltd.
    • Novo Holdings（Catalent, Inc.）
    • Thermo Fisher Scientific, Inc.
    • Siegfried Holding AG
    • Recipharm AB
    • CordenPharma International
    • Samsung Biologics
    • Labcorp
    • Ajinomoto Bio-Pharma Services
    • Piramal Pharma Solutions
    • Jubilant Life Sciences（Jubilant Biosys Limited）
    • WuXi AppTec Co., Ltd.
Product Code: GVR-4-68040-250-0

Small Molecule Innovator API CDMO Market Growth & Trends:

The global small molecule innovator API CDMO market size is expected to reach USD 47.14 billion by 2030, registering a CAGR of 6.53% from 2024 to 2030, according to a new report by Grand View Research, Inc. A growing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and a surge in the number of clinical trials are anticipated to influence the market positively. The growing utilization of CDMOs in the pharmaceutical sector stems from various reasons, with cost-effectiveness as the prominent factor. Outsourcing emerges as an efficient strategy for pharmaceutical firms to reduce expenses by sidestepping the necessity for costly infrastructure and equipment investments. CDMOs offer the requisite expertise and infrastructure to deliver drug development and manufacturing services in a financially prudent manner.

Furthermore, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules. In addition, several pharmaceutical companies prefer CDMOs to access advanced infrastructure and expertise due to the increasing influx of novel therapies & orphan drugs and higher returns on approved products. Moreover, continuous technological advancements among CDMOs offer innovative small molecule APIs to meet the growing demands for innovation, efficiency, and regulatory compliance in the healthcare industry.

The adoption of advanced technologies by companies enhances drug development, manufacturing processes, and productivity. The increasing demand for new small molecule innovator API in the pharmaceutical industry is encouraging commercial CDMOs to expand their capabilities, which is expected to boost market growth. For instance, in August 2023, Astex announced a research collaboration & license agreement with MSD to classify small molecule candidates with tumor suppressor proteins for cancer treatment. Under the agreement, the company will use its fragment-based drug discovery platform to develop compounds and provide MSD with main compounds for preclinical development & optimization.

Small Molecule Innovator API CDMO Market Report Highlights:

  • The clinical stage type segment dominated the market with a share of 54.68% in 2023. Growth in the segment can be attributed to the rising clinical trial (phase I-III) activities for diverse formulations, growing small molecule development pipeline, increasing availability of specialized expertise, timesaving & cost-efficiency for investigational drugs, and innovations. Moreover, rising funding for drug development is propelling segment growth
  • Based on the customer type, the pharmaceutical segment held the largest share in 2023 due to rapid advancements in pharmaceutical R&D for the development of advanced drugs. In addition, advancements in various therapies have shifted pharmaceutical companies' focus on CDMOs to developing novel small molecule innovator API drugs to treat numerous diseases
  • The oncology therapeutic area segment dominated the market and accounted for a share of 42.25% in 2023. The segment growth is driven by the increasing prevalence of cancer globally. In addition, growing demand for innovative small molecule innovator APIs, advancements in targeted therapies, and demand for oncology drugs innovations are the factors driving the oncology segment
  • Asia Pacific dominated the market with a share of 41.53% in 2023 due to increasing prevalence of chronic diseases, demand for small molecule APIs & CDMO services, and improving healthcare infrastructure

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
    • 1.3.5. Details of Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. Market Definitions
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives
    • 1.10.1. Objective - 1
    • 1.10.2. Objective - 2
    • 1.10.3. Objective - 3
    • 1.10.4. Objective - 4

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Small Molecule Innovator API CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Ancillary Market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Demand for Small Molecule Drugs
      • 3.2.1.2. Increasing Outsourcing Trends Among Pharmaceutical Companies
      • 3.2.1.3. Surge in Number of Clinical Trials
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Compliance Issues While Outsourcing
      • 3.2.2.2. Changing Scenarios in Developing Economies
  • 3.3. Technology Landscape
    • 3.3.1. Integration Of Ai In Small Molecule Innovator API CDMO Market
      • 3.3.1.1. Current Dynamics and Future Trends
      • 3.3.1.1.1. Drug Discovery and Design
      • 3.3.1.1.2. AI-Assisted Drug API Synthesis
      • 3.3.1.1.3. Process Optimization
      • 3.3.1.1.4. Supply Chain Management
      • 3.3.1.1.5. Clinical Trial Optimization
      • 3.3.1.1.6. Regulatory Compliance
  • 3.4. Total Number of Clinical Trials by Phase & Region (2021 - 2023)
    • 3.4.1. Total Number of Clinical Trials by Phase (2021 - 2023)
    • 3.4.2. Total Number of Clinical Trials by Region (2021 - 2023)
      • 3.4.2.1. Percentage of Clinical Trials by Major Countries in North America:
      • 3.4.2.2. Percentage of Clinical Trials by Major Countries in Europe:
      • 3.4.2.3. Percentage of Clinical Trials by Major Countries in Asia Pacific:
      • 3.4.2.4. Percentage of Clinical Trials by Major Countries in Latin America:
      • 3.4.2.5. Percentage of Clinical Trials by Major Countries in the Middle East & Africa:
    • 3.4.3. Total Number of Clinical Trials by Therapeutic Area (2021 - 2023)
  • 3.5. Small Molecule Innovator API CDMO Market: Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTEL Analysis
  • 3.6. Impact of COVID-19 on Small Molecule Innovator CDMO Market
  • 3.7. COVID-19 Impact Analysis

Chapter 4. Small Molecule Innovator API CDMO Market: Stage Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Small Molecule Innovator API CDMO Market Movement Analysis
  • 4.3. Global Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Stage Type, 2018 to 2030 (USD Million)
    • 4.3.1. Preclinical
      • 4.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.3.2. Clinical
      • 4.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.3.2.2. Phase I
      • 4.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.3.2.3. Phase II
      • 4.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.3.2.4. Phase III
      • 4.3.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.3.3. Commercial
      • 4.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Small Molecule Innovator API CDMO Market: Customer Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Small Molecule Innovator API CDMO Market Movement Analysis
  • 5.3. Global Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Customer Type, 2018 to 2030 (USD Million)
    • 5.3.1. Pharmaceutical
      • 5.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 5.3.1.2. Small
      • 5.3.1.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 5.3.1.3. Medium
      • 5.3.1.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 5.3.1.4. Large
      • 5.3.1.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 5.3.2. Biotechnology
      • 5.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 5.3.2.2. Small
      • 5.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 5.3.2.3. Medium
      • 5.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 5.3.2.4. Large
      • 5.3.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Small Molecule Innovator API CDMO Market: Therapeutic Area Estimates & Trend Analysis

  • 6.1. Definitions and Scope
    • 6.1.1. Cardiovascular Diseases
    • 6.1.2. Oncology
    • 6.1.3. Respiratory Disorders
    • 6.1.4. Neurology
    • 6.1.5. Metabolic Disorders
    • 6.1.6. Infectious Diseases
    • 6.1.7. Others
  • 6.2. Therapeutic Area Market Share, 2023 & 2030
  • 6.3. Segment Dashboard
  • 6.4. Global Small Molecule Innovator API CDMO Market Movement Analysis
  • 6.5. Global Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
    • 6.5.1. Cardiovascular Diseases
      • 6.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.2. Oncology
      • 6.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.3. Respiratory Disorders
      • 6.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.4. Neurology
      • 6.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.5. Metabolic Disorders
      • 6.5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.6. Infectious Diseases
      • 6.5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.7. Others
      • 6.5.7.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Small Molecule Innovator API CDMO Market: Regional Estimates & Trend Analysis by Product, Workflow, & Application

  • 7.1. Regional Market Dashboard
  • 7.2. Global Regional Market Snapshot
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Scenario
      • 7.4.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Scenario
      • 7.4.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Scenario
      • 7.5.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Scenario
      • 7.5.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Scenario
      • 7.5.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Scenario
      • 7.5.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Scenario
      • 7.5.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Scenario
      • 7.5.7.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Scenario
      • 7.5.8.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Scenario
      • 7.5.9.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Scenario
      • 7.6.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.3. Japan
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Scenario
      • 7.6.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Scenario
      • 7.6.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Scenario
      • 7.6.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Scenario
      • 7.6.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Scenario
      • 7.6.7.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.8. Taiwan
      • 7.6.8.1. Key Country Dynamics
      • 7.6.8.2. Competitive Scenario
      • 7.6.8.3. Regulatory Scenario
      • 7.6.8.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Scenario
      • 7.7.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.7.3. Mexico
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Scenario
      • 7.7.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.7.4. Argentina
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Scenario
      • 7.7.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Scenario
      • 7.8.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Scenario
      • 7.8.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Scenario
      • 7.8.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Scenario
      • 7.8.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.8.6. Israel
      • 7.8.6.1. Key Country Dynamics
      • 7.8.6.2. Competitive Scenario
      • 7.8.6.3. Regulatory Scenario
      • 7.8.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Service Heat Map Analysis (a comparative analysis of the players together)
  • 8.3. Company Profiles
  • 8.4. Company Profiles
    • 8.4.1. Strategy Mapping
    • 8.4.2. Expansion
    • 8.4.3. Partnerships
    • 8.4.4. Acquisitions
  • 8.5. Vendor Landscape
    • 8.5.1. Key company market share analysis, 2023
    • 8.5.2. Lonza Group Ltd.
      • 8.5.2.1. Company overview
      • 8.5.2.2. Financial performance
      • 8.5.2.3. Product/service benchmarking
      • 8.5.2.4. Strategic initiatives
    • 8.5.3. Novo Holdings (Catalent, Inc.)
      • 8.5.3.1. Company overview
      • 8.5.3.2. Financial performance
      • 8.5.3.3. Product/service benchmarking
      • 8.5.3.4. Strategic initiatives
    • 8.5.4. Thermo Fisher Scientific, Inc.
      • 8.5.4.1. Company overview
      • 8.5.4.2. Financial performance
      • 8.5.4.3. Product/service benchmarking
      • 8.5.4.4. Strategic initiatives
    • 8.5.5. Siegfried Holding AG
      • 8.5.5.1. Company overview
      • 8.5.5.2. Financial performance
      • 8.5.5.3. Product/service benchmarking
      • 8.5.5.4. Strategic initiatives
    • 8.5.6. Recipharm AB
      • 8.5.6.1. Company overview
      • 8.5.6.2. Financial performance
      • 8.5.6.3. Product/service benchmarking
      • 8.5.6.4. Strategic initiatives
    • 8.5.7. CordenPharma International
      • 8.5.7.1. Company overview
      • 8.5.7.2. Financial performance
      • 8.5.7.3. Product/service benchmarking
      • 8.5.7.4. Strategic initiatives
    • 8.5.8. Samsung Biologics
      • 8.5.8.1. Company overview
      • 8.5.8.2. Financial performance
      • 8.5.8.3. Product/service benchmarking
      • 8.5.8.4. Strategic initiatives
    • 8.5.9. Labcorp
      • 8.5.9.1. Company overview
      • 8.5.9.2. Financial performance
      • 8.5.9.3. Product/service benchmarking
      • 8.5.9.4. Strategic initiatives
    • 8.5.10. Ajinomoto Bio-Pharma Services
      • 8.5.10.1. Company overview
      • 8.5.10.2. Financial performance
      • 8.5.10.3. Product/service benchmarking
      • 8.5.10.4. Strategic initiatives
    • 8.5.11. Piramal Pharma Solutions
      • 8.5.11.1. Company overview
      • 8.5.11.2. Financial performance
      • 8.5.11.3. Product/service benchmarking
      • 8.5.11.4. Strategic initiatives
    • 8.5.12. Jubilant Life Sciences (Jubilant Biosys Limited)
      • 8.5.12.1. Company overview
      • 8.5.12.2. Financial performance
      • 8.5.12.3. Product/service benchmarking
      • 8.5.12.4. Strategic initiatives
    • 8.5.13. WuXi AppTec Co., Ltd.
      • 8.5.13.1. Company overview
      • 8.5.13.2. Financial performance
      • 8.5.13.3. Product/service benchmarking
      • 8.5.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 4 North America Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 5 North America Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 6 U.S. Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 7 U.S. Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 8 U.S. Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 9 Canada Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 10 Canada Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 11 Canada Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 12 Europe Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 14 Europe Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 15 Europe Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 16 UK Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 17 UK Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 18 UK Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 19 Germany Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 20 Germany Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 21 Germany Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 22 France Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 23 France Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 24 France Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 25 Italy Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 26 Italy Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 27 Italy Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 28 Spain Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 29 Spain Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 30 Spain Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 31 Denmark Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 32 Denmark Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 33 Denmark Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 34 Sweden Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 35 Sweden Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 36 Sweden Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 37 Norway Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 38 Norway Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 39 Norway Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 44 China Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 45 China Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 46 China Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 47 Japan Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 48 Japan Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 49 Japan Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 50 India Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 51 India Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 52 India Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 53 Australia Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 54 Australia Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 55 Australia Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 56 South Korea Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 57 South Korea Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 59 Thailand Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 60 Thailand Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 61 Thailand Taiwan Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 62 Taiwan Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 63 Taiwan Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 64 Taiwan Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 65 Latin America Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 66 Latin America Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 67 Latin America Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 68 Latin America Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 69 Brazil Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 70 Brazil Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 71 Brazil Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 72 Mexico Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 73 Mexico Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 74 Mexico Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 75 Argentina Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 76 Argentina Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 78 MEA Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 79 MEA Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 80 MEA Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 81 MEA Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 82 South Africa Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 83 South Africa Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 84 South Africa Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 88 UAE Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 89 UAE Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 91 Kuwait Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 94 Israel Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 95 Israel Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 96 Israel Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Small molecule innovator API CDMO market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Value-Chain-Based Sizing & Forecasting
  • Fig. 9 QFD model sizing & forecasting
  • Fig. 10 Bottom-up approach
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Parent market outlook, 2023(USD Million)
  • Fig. 16 Ancillary market outlook, 2023 (USD Million)
  • Fig. 17 Small molecule innovator API CDMO market dynamics
  • Fig. 18 FDA's novel drug approvals in 2023
  • Fig. 19 Percentage of clinical trials by major countries in North America
  • Fig. 20 Percentage of clinical trials by major countries in Europe
  • Fig. 21 Percentage of clinical trials by major countries in Asia Pacific
  • Fig. 22 Percentage of clinical trials by major countries in Latin America
  • Fig. 23 Percentage of clinical trials by major countries in Middle East & Africa
  • Fig. 24 Porter's five forces analysis
  • Fig. 25 Small molecule innovator API CDMO market: PESTEL analysis
  • Fig. 26 Small molecule innovator API CDMO market: Stage Type outlook and key takeaways
  • Fig. 27 Small molecule innovator API CDMO market: Stage type movement analysis
  • Fig. 28 Preclinical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Clinical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Phase I small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Phase II small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Phase III small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Commercial small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Small molecule innovator API CDMO market: Customer type outlook and key takeaways
  • Fig. 35 Small molecule innovator API CDMO market: Customer type movement analysis
  • Fig. 36 Pharmaceutical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Small pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Medium pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Large pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Biotechnology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Small biotechnology customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Medium biotechnology customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Large biotechnology customer in small molecule molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Small molecule innovator API CDMO market: Therapeutic area outlook and key takeaways
  • Fig. 45 Small molecule innovator API CDMO market: Therapeutic area movement analysis
  • Fig. 46 Cardiovascular diseases small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Oncology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Respiratory disorders small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Neurology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Metabolic disorders small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Infectious diseases small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Others small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Regional market: Key takeaways
  • Fig. 54 Regional outlook, 2023 & 2030
  • Fig. 55 Regional outlook, 2023 & 2030
  • Fig. 56 North America small molecule innovator API CDMO market, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 U.S. small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Canada small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Europe small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 UK small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Germany small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 France small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Italy small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Spain small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Denmark small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Sweden small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Norway small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Rest of Europe small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 MEA small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 South Africa small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Saudi Arabia small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Clinical trial authorization process UAE
  • Fig. 86 UAE small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Regulatory framework: South Africa
  • Fig. 89 Kuwait small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 Israel small molecule innovator API CDMO estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Rest of Europe small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Asia Pacific small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 China small molecule innovator API CDMO estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Key country dynamics
  • Fig. 97 Regulatory bodies in India involved in pharmaceutical regulations
  • Fig. 98 India small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Key country dynamics
  • Fig. 100 Clinical trial authorization process in Japan
  • Fig. 101 Clinical research of medical products in Japan
  • Fig. 102 Japan small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Key country dynamics
  • Fig. 104 Australia small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Key country dynamics
  • Fig. 106 Clinical trial approval process in South Korea
  • Fig. 107 South Korea small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 Key country dynamics
  • Fig. 109 Thailand small molecule innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 Key country dynamics
  • Fig. 111 Taiwan small molecule innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 112 Rest of APAC small molecule innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Key country dynamics
  • Fig. 114 Brazil small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 115 Key country dynamics
  • Fig. 116 Mexico small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 117 Key country dynamics
  • Fig. 118 Argentina pharmaceuticals registration details
  • Fig. 119 Argentina small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 120 Market participant categorization
  • Fig. 121 Heat map analysis
  • Fig. 122 Market participant categorization